The Complete List of GxP Types, Acronyms, and Core Domains - GxP Compliance Framework
The Complete List of GxP Types, Acronyms, and Core Domains
(Chapter 14 of GxP Compliance Framework)
Executive Summary: Chapter Overview
IF4ITThe Bottom Line
Core Concepts
| Concept | Definition & Strategic Role |
|---|---|
| Alphabetical Ordering by Abbreviation | The catalog is sorted by Abbreviation/Acronym rather than by Core Domain, so acronym collisions across different domains sit directly adjacent to each other for quick disambiguation. |
| Verified, Not Inherited | Every entry was checked against original regulatory or industry-body sources during drafting rather than assumed accurate from initial research — several corrections resulted. |
| Not Exhaustive | This catalog documents the most commonly recognized GxP disciplines, consistent with this Framework’s stated scope — see “Identify Additional or Emerging Forms of GxP Relevant to Your Enterprise” for disciplines beyond this list. |
Quick Q&A
Question: Why is this table sorted alphabetically by abbreviation instead of by domain?
Question: Does every entry in this table have a single, clearly identifiable Regulatory Body?
Read More Below
Overview
This chapter consolidates every GxP discipline confirmed across the five domain chapters in “The GxP Product Lifecycle” and the “Core Foundations of GxP Compliance” subsection into a single reference table. Twenty-one disciplines are documented here — each checked against its actual governing regulatory or industry body during the drafting of this Framework, rather than carried forward unverified from initial research. That verification process caught a meaningful number of errors along the way: several acronyms in early drafts turned out not to be real, standalone disciplines at all, and three genuine, confirmed collisions surfaced where two entirely different disciplines share the same abbreviation — GCP, GEP, and GPP.
The table is sorted alphabetically by Abbreviation/Acronym rather than by Core Domain. This is a deliberate choice tied to this Framework’s central theme, introduced in “Why GxP Acronyms and Abbreviations Overlap”: when two disciplines share an abbreviation, alphabetical ordering places their entries directly next to each other, so the difference is immediately visible rather than requiring a search across separate domain chapters.
As stated in this Framework’s Overview, this catalog documents the most commonly recognized GxP disciplines — it is a foundation, not an exhaustive list. With every discipline now resolved to its real name, Core Domain, and regulatory body, the next step is assigning clear internal accountability for each one — addressed directly in “Assign Ownership and Governance for Each GxP Discipline,” immediately following this chapter.
| Full Name (Singular) | Full Name (Plural) | Abbreviation/Acronym | Core Domain | Description and Purpose(s) | Benefit(s) | Suggested Ownership | Regulatory Body/Bodies |
|---|---|---|---|---|---|---|---|
| Good Agricultural and Collection Practice | Good Agricultural and Collection Practices | GACP | Upstream Research and Development (R&D) | Governs cultivation, harvesting, and collection of medicinal plants and herbal starting materials to ensure raw material purity and consistency. | Prevents raw material variability from ever entering the development pipeline, protecting every dollar invested downstream. | R&D / Procurement (Raw Material Sourcing) | World Health Organization (WHO); European Medicines Agency (EMA) |
| Good Automated Manufacturing Practice | Good Automated Manufacturing Practices | GAMP | Manufacturing, Engineering, and Technology | Provides a risk-based lifecycle framework for validating automated machinery, enterprise software, and IT infrastructure in regulated manufacturing. | Focuses validation effort proportionally to actual risk, avoiding both under-validated systems and wasted spend on excessive rigor. | Quality Assurance / Computerized Systems Validation | International Society for Pharmaceutical Engineering (ISPE) |
| Good Auditing Practice | Good Auditing Practices | GAP | Cross-Functional Operations and Business Governance | Governs internal and vendor compliance audits verifying adherence to other GxP disciplines such as GMP, GCP, and GLP. | Surfaces compliance gaps internally before a regulator finds them during inspection. | Compliance / Internal Audit | Industry practitioner convention — no single codifying body |
| Good Cell and Tissue Culture Practice | Good Cell and Tissue Culture Practices | GCCP | Upstream Research and Development (R&D) | Governs the growth, handling, and maintenance of living cell and tissue cultures to prevent contamination and ensure reproducible research data. | Protects the reproducibility of research findings that later-stage trials and manufacturing will depend on. | R&D / Laboratory Operations | European Centre for the Validation of Alternative Methods (ECVAM) |
| Good Clinical Data Management Practice | Good Clinical Data Management Practices | GCDMP | Clinical Development and Patient Studies | Governs Electronic Data Capture system design, real-time data recording, database locking, and medical coding for regulatory submission. | Shortens regulatory review timelines by reducing data-integrity queries during submission. | Clinical Data Management / Biometrics | Society for Clinical Data Management (SCDM) |
| Good Clinical Laboratory Practice | Good Clinical Laboratory Practices | GCLP | Clinical Development and Patient Studies | Hybrid standard applying GLP's data-integrity discipline and GCP's subject-protection principles to laboratories analyzing clinical trial samples. | Closes the specific gap neither GLP nor GCP covers alone, protecting the reliability of trial sample results. | Clinical Operations / Central Laboratory | Research Quality Association (RQA); WHO; MHRA |
| Good Clinical Practice | Good Clinical Practices | GCP | Clinical Development and Patient Studies | Governs the design, conduct, recording, and reporting of human clinical trials — protocol adherence, informed consent, and ethics oversight. | Directly protects the safety of human trial participants, the ethical foundation the entire discipline exists to uphold. | Clinical Quality / GCP Compliance | International Council for Harmonisation (ICH E6); FDA; EMA |
| Good Computational Practice | Good Computational Practices | GCP | Upstream Research and Development (R&D) | Governs validation and reproducibility of computational modeling, molecular simulation, and in silico research methods. | Builds regulator confidence in modeling-based evidence as its role in drug development expands. | R&D / Computational Sciences | No single codifying body — emerging discipline |
| Good Documentation Practice | Good Documentation Practices | GDocP | Cross-Functional Operations and Business Governance | Establishes non-negotiable ALCOA+ documentation rules for paper and electronic records across every department. | Makes every other GxP discipline's compliance claims verifiable, since none of them hold up without adequate documentation. | Compliance / Quality Assurance (Enterprise-Wide) | Embedded in FDA, EMA, and WHO cGMP-family guidance |
| Good Distribution Practice | Good Distribution Practices | GDP | Supply Chain, Logistics, and Commercial Distribution | Governs the secure wholesale movement of pharmaceutical products — storage conditions, transport, and handling — from manufacturer to point of sale. | Preserves product efficacy through the wholesale chain, protecting the value of everything built in Manufacturing. | Supply Chain / Distribution Compliance | EU (Directive 2001/83/EC); FDA; WHO |
| Good Engineering Practice | Good Engineering Practices | GEP | Manufacturing, Engineering, and Technology | Governs facility and utility qualification — water systems, HVAC cleanrooms, and processing equipment — to defined engineering standards. | Prevents facility and utility failures from becoming the root cause of a manufacturing deviation. | Engineering / Facilities | International Society for Pharmaceutical Engineering (ISPE); FDA and EMA expectations |
| Good Experimental Practice | Good Experimental Practices | GEP | Upstream Research and Development (R&D) | Governs structured experimental design and environmental controls for early-stage, non-regulated exploratory laboratory research. | Ensures early discovery findings can be independently replicated before significant investment follows them. | R&D / Laboratory Operations | No single codifying body — practitioner convention |
| Good Hygiene Practice | Good Hygiene Practices | GHP | Upstream Research and Development (R&D) | Enforces environmental sanitation, pest control, and personnel hygiene in early-stage material handling areas. | Provides a baseline contamination control that protects every downstream domain's outcomes. | R&D / Environmental Health and Safety | Codex Alimentarius Commission (FAO/WHO) |
| Good Manufacturing Practice | Good Manufacturing Practices | GMP | Manufacturing, Engineering, and Technology | Governs full-scale commercial batch production, quality control laboratory testing, and cleaning validation to guarantee every batch meets specification. | Makes "every batch meets specification" a reliable, auditable claim rather than a hopeful one. | Quality Assurance (Manufacturing Compliance & Batch Release) | FDA; EMA; WHO; ICH Q7 |
| Good Pharmacoepidemiology Practice | Good Pharmacoepidemiology Practices | GPP | Clinical Development and Patient Studies | Governs observational, population-level studies — including post-authorization safety studies — assessing a product's real-world outcomes. | Catches real-world safety signals faster, protecting patients using an approved product today. | Clinical / Real-World Evidence | International Society for Pharmacoepidemiology (ISPE) |
| Good Pharmacy Practice | Good Pharmacy Practices | GPP | Supply Chain, Logistics, and Commercial Distribution | Governs dispensing safety, compounding controls, and patient-facing standards at retail and clinical pharmacies. | Protects patients at the exact point where a product transitions from supply chain custody to individual use. | Commercial / Pharmacy Compliance | International Pharmaceutical Federation (FIP); WHO |
| Good Quality Practice | Good Quality Practices | GQP | Cross-Functional Operations and Business Governance | Governs the overall Quality Management System, CAPA programs, and enterprise risk frameworks under Japan's Pharmaceutical Affairs Law. | Gives the Japanese marketing authorization holder a single accountable quality framework spanning manufacturing and distribution. | Compliance / Quality Assurance (Japan Marketing Authorization Holder) | Ministry of Health, Labour and Welfare (MHLW); PMDA (Japan) |
| Good Storage Practice | Good Storage Practices | GSP | Supply Chain, Logistics, and Commercial Distribution | Governs the quality-assurance controls required to maintain product integrity throughout warehousing and storage. | Prevents storage-condition failures from silently degrading product quality before it ever reaches transit. | Supply Chain / Warehouse Operations | World Health Organization (WHO) |
| Good Trade and Distribution Practice | Good Trade and Distribution Practices | GTDP | Supply Chain, Logistics, and Commercial Distribution | Governs quality-assurance controls throughout international trade and cross-border distribution, including customs clearance and quarantine handling. | Reduces customs delays directly, getting time-sensitive treatments to patients faster across borders. | Supply Chain / Trade Compliance | World Health Organization (WHO) |
| Good Tissue Practice | Good Tissue Practices | GTP | Upstream Research and Development (R&D) | Governs recovery, donor screening, processing, and storage of human cells and tissue-based products to prevent contamination and disease transmission. | Prevents contamination or disease transmission in one of the most safety-sensitive categories of regulated product. | Regulatory Compliance / Tissue Bank Operations | FDA (21 CFR Part 1271) |
| Good Pharmacovigilance Practice | Good Pharmacovigilance Practices | GVP | Cross-Functional Operations and Business Governance | Governs post-market safety surveillance and adverse event reporting throughout a product's lifecycle, even after approval. Also referred to as Good Vigilance Practice in some jurisdictions, including Japan. | Protects patients using an approved product long after the controlled conditions of a clinical trial have ended. | Drug Safety / Pharmacovigilance Compliance | EMA (GVP Modules I–XVI); FDA; ICH E2 |
Three collisions are worth highlighting explicitly, since they’re easy to miss scanning quickly: GCP appears twice — Good Clinical Practice governs human trials in Clinical Development, while Good Computational Practice governs modeling and simulation in Upstream Research and Development. GEP appears twice — Good Engineering Practice governs facilities and equipment in Manufacturing, while Good Experimental Practice governs early-stage laboratory research in Upstream R&D. And GPP appears twice — Good Pharmacoepidemiology Practice governs population-level safety studies in Clinical Development, while Good Pharmacy Practice governs dispensing and compounding in Supply Chain and Commercial Distribution. In every case, the Full Name and Core Domain columns resolve the ambiguity — never rely on the bare abbreviation alone.
The Regulatory Body/Bodies column itself is worth treating as more than a citation. The FDA, EMA, WHO, ICH, and the dozen-plus other agencies and industry bodies named throughout this table each have a fuller profile — mandate, jurisdiction, and scope — documented in IF4IT’s Regulatory Agencies Inventory and Attributes document. Cross-referencing a discipline’s regulatory body against that inventory is a natural next step whenever a compliance decision depends on understanding an agency’s authority in more depth than this Framework provides.
Best Practice
Use this table as your first stop when encountering an unfamiliar GxP acronym, and treat it as a starting point for verification rather than a final legal authority — regulatory guidance changes, and this catalog reflects the most commonly recognized disciplines as understood at the time of writing. When a specific compliance decision depends on a discipline’s exact current requirements, always confirm against the named Regulatory Body’s current published guidance directly.
Benefit(s)
A single, verified, alphabetically searchable catalog eliminates the single most common source of GxP confusion this Framework has identified across every domain chapter: acting on an unverified or partially remembered acronym. It also gives an enterprise a defensible, documented position during an audit — able to show not just that a discipline was followed, but that the organization correctly identified which discipline applied, which regulatory body defined it, and who internally was accountable for it.
How to cite this page
When referencing this page in academic work, internal standards, or external publications, include the page title, IF4IT as author and publisher (The International Foundation for Information Technology (IF4IT), LLC), the URL, and your access date.
Example (informal web citation):
The International Foundation for Information Technology (IF4IT), LLC. The Complete List of GxP Types, Acronyms, and Core Domains | GxP Compliance Framework. https://if4it.org/best-practices/gxp-compliance-framework/the-complete-list-of-gxp-types-acronyms-and-core-domains/ (accessed 2026-09-04).
See About Us for content governance and site-wide citation guidance.
Copyright for The International Foundation for Information Technology (IF4IT), LLC: 2008 - Present
Legal Disclaimers